.jpg)
.png)
Spring 2020
In 2019, the Centers for Disease Control and Prevention reported that prevalence for both obesity and overweight have continued to rise over the last eight years and are at an all-time high for adults and adolescents.(1) Approximately two-thirds of US adults are either obese (31%) or overweight (35... more
I would like to wish everyone a Happy New Year! With the new year upon us and being more than halfway through my term as President, I wanted to thank the membership for the opportunity to provide a reminder of a few key initiatives of the NLA and make sure you complete your 2020 NLA checklist... more
While expertise in lipids management has evolved over many decades, our field of lipidology truly took flight in 2006 with the American Board of Clinical Lipidology certification process. Since those early days, we have slowly but steadily raised awareness of the value of the care we provide as... more
“People who believe they are ignorant of nothing have neither looked for nor stumbled upon the boundary between what is known and unknown in the universe” — Neil deGrasse Tyson It is a privilege as the co-editor of the LipidSpin to write the Editor’s Corner for the Midwest (MWLA) edition of... more
Nonalcoholic fatty liver disease (NAFLD) is the main hepatic complication of obesity, diabetes and metabolic syndrome. Its prevalence has risen dramatically since 1980, when it was a perplexing and sporadically-observed disease as first reported by Ludwig and colleagues (1), to a current... more
Although there is debate over the definition of metabolic syndrome in adults, the picture is even more clouded in pediatrics. Metabolic syndrome in adults is defined as having at least three of the following five cardiometabolic risk factors: hyperglycemia, increased central adiposity, elevated... more
Results from multiple trials prompted the Food and Drug Administration’s (FDA) approval of empagliflozin (Jardiance) for reducing cardiovascular (CV) death and canagliflozin (Invokana) for reducing CV death and CV events, in patients with cardiovascular disease and type II diabetes (T2D).(1-6) The... more
Fabry’s Disease and Morquio A syndrome are two rare genetic diseases that lead to a diverse series of problems including cardiovascular.(1,30) Until recently, treatment options have been limited to treat these conditions. Now that there are available therapies to help improve quality and quantity... more
Introduction Elevated cholesterol is a well-known and modifiable risk factor for cardiovascular disease. Hyperlipidemia due to secondary causes is common and should be evaluated as part of treatment. Potential secondary causes include diabetes mellitus, excessive alcohol intake, cholestatic... more